Cannabis Report
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 9/24/2018 12:37:10 PM - Followers: 155 - Board type: Free - Posts Today: 7

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#7033  Sticky Note Biggest and Best Aurinia Presentation to date (163 pages) moosedogger 05/07/18 09:48:57 AM
#7478   LTD, this will provide you wealth: Aurinia And Voclosporin: biotech_researcher 09/24/18 12:37:10 PM
#7477   "Aurinia And Voclosporin: Making A Difference In Focal moosedogger 09/24/18 12:36:54 PM
#7476   Lol it's ok, just happy for anyone making LivingTheDream 09/24/18 10:50:20 AM
#7475   This is not the AMRN board... biotech_researcher 09/24/18 10:33:42 AM
#7474   No I didn't,but good for you BR for zzaatt 09/24/18 10:28:54 AM
#7473   No I didn't,but good for you BR for LivingTheDream 09/24/18 09:24:27 AM
#7472   I hope everyone had some AMRN. Stunning ph biotech_researcher 09/24/18 07:14:35 AM
#7471   Hi Moose. I’m not sure if full enrollment biotech_researcher 09/22/18 09:10:47 AM
#7470   ".....the rest of my small biotechs are doing moosedogger 09/22/18 08:57:47 AM
#7469   Another day of disappointing action in AUPH stock. biotech_researcher 09/21/18 03:27:53 PM
#7468   Aurinia to Participate in Upcoming Investor Conferences moosedogger 09/19/18 04:27:34 PM
#7467   Should have a couple full enrollment announcements coming Lunacy aka John Galt 09/19/18 02:32:50 PM
#7466   Fat finger trade? biotech_researcher 09/19/18 12:44:47 PM
#7465   AUPH's YTD chart sure looks good. somerssalt 09/19/18 12:35:16 PM
#7464   Almost a million shares (900K) at noon.... Why? zzaatt 09/19/18 12:15:15 PM
#7463   Almost a million shares (900K) at noon.... biotech_researcher 09/19/18 12:08:27 PM
#7462   Big volume spike today including a reported single moosedogger 09/19/18 10:41:19 AM
#7461   I agree LivingTheDream 09/17/18 12:07:11 PM
#7460   I'm guessing we all pretty much agree- we moosedogger 09/17/18 11:41:44 AM
#7459   Higher the number more volatility more risk more LivingTheDream 09/17/18 11:04:26 AM
#7458   Low institutional ownership (like 25%) is negative for zzaatt 09/17/18 10:55:49 AM
#7457   Well, in my book, a high institutional ownership biotech_researcher 09/17/18 10:39:54 AM
#7456   Thanks for checking.....BTW, what I said is partially moosedogger 09/17/18 09:41:44 AM
#7455   Thanks Moose. I will do that and report back.. biotech_researcher 09/17/18 09:13:35 AM
#7454   "Aurinia has only 25% institutional ownership." moosedogger 09/17/18 08:36:24 AM
#7453  Restored Chris Perozzi (@ThunderUp013) 9/15/18, 10:44 AM ??@jimcramer?? Which made you biotech_researcher 09/17/18 05:03:13 AM
#7452   Pretty pathetic. Aurinia has only 25% institutional ownership. biotech_researcher 09/15/18 11:49:11 AM
#7451   Smooth move by Auph biotech_researcher 09/14/18 03:55:49 PM
#7450   The source of that SA article re Aurinia moosedogger 09/10/18 02:49:02 PM
#7449   "2018 Is An Ideal Entry Point For Aurinia Pharmaceuticals" moosedogger 09/10/18 02:02:28 PM
#7448   "Maybe they should buy out smaller bios." moosedogger 09/04/18 12:46:27 PM
#7447   AstraZ has drugs failing trials left and right. tiv111 09/03/18 11:04:56 AM
#7446   more on AstraZeneca Phase 3 failure in SLE: moosedogger 09/03/18 09:18:43 AM
#7445   You’re right in that there are too many Lunacy aka John Galt 08/31/18 06:13:19 PM
#7444   I dont believe these other trials that have tiv111 08/31/18 06:06:56 PM
#7443   I assume that this could be interpreted as Maciste 08/31/18 02:35:02 PM
#7442   I believe October is when Jess guessed some moosedogger 08/31/18 01:04:47 PM
#7441 lidopete 08/31/18 10:44:55 AM
#7440   AstraZeneca's recent troubles remind me that, according to Zeppo 08/31/18 10:17:25 AM
#7439   "AstraZeneca lupus drug fails to meet main goal moosedogger 08/31/18 09:19:14 AM
#7438   Time of disbursement has not been disclosed yet Hotrodder1 08/31/18 07:52:43 AM
#7437   Have you received a payout? If so, nsomniyak 08/30/18 09:03:39 PM
#7436   PS. Ariad suit settlement was approved by Judge Hotrodder1 08/30/18 08:28:10 PM
#7435   It’s tough when you have over 5 thousand Hotrodder1 08/30/18 08:25:33 PM
#7434   Luna- thanks for your comments and for the moosedogger 08/30/18 05:15:59 PM
#7433   Luna, “For as much promise as AUPH has”.... ThePromise247 08/30/18 02:54:20 PM
#7432   Don’t crush that dwarf, hand me the pliers... nsomniyak 08/30/18 01:33:22 PM
#7431   Crush that dwarf..... biotech_researcher 08/30/18 12:48:28 PM
#7430   It looks like the last couple days of Maciste 08/30/18 11:58:46 AM
#7429   Moose, for as much promise as Auph has Lunacy aka John Galt 08/30/18 10:33:37 AM